Piezoelectric Fingers Key in New Breast Cancer Detector

Key points
- Researchers at Drexel University are developing a new portable, low-cost, radiation-free breast cancer detector that can be used in a doctor’s office as a first-line to detect breast cancer in younger women and in women over 40 with mammographically dense-tissue breasts.
- Shih, a breast cancer survivor and an associate professor in Drexel’s School of Biomedical Engineering, Science and Health Systems, Dr.
- To date the only FDA-approved breast cancer screening system in the U.S. is mammography beginning at age 40 for women.
- The effectiveness of this screening device is lessened in women with dense breasts.
Researchers at Drexel University are developing a new portable, low-cost, radiation-free breast cancer detector that can be used in a doctor’s office as a first-line to detect breast cancer in younger women and in women over 40 with mammographically dense-tissue breasts. The detector is based on piezoelectric fingers (an elastic and shear modulus sensor) developed at Drexel. In evaluations on tumor specimens, it has positively identified a 3mm tumor previously missed by mammography, ultrasound and the physician’s palpation.
The researchers, Dr. Wan Y. Shih, a breast cancer survivor and an associate professor in Drexel’s School of Biomedical Engineering, Science and Health Systems, Dr. Wei-Heng Shih, a professor in Drexel’s materials science and engineering department and Dr. Ari D. Brooks, an associate professor of surgery at the Drexel University College of Medicine, expect to develop a portable, radiation-free, breast-scanning device that is not only capable of locating small tumors of any type, but also able to predict tumor malignancy. The proposed screening tool will be positioned as an early breast cancer screening tool to be used by physicians and gynecologists in the clinical setting in conjunction with the physical examination. It supplements mammography to screen early for breast cancer in women with dense-tissue breasts. In countries such as China and India, where mammography is not readily available due to cost, the PEF device can be used as a primary screening tool.
To date the only FDA-approved breast cancer screening system in the U.S. is mammography beginning at age 40 for women.
The effectiveness of this screening device is lessened in women with dense breasts. A mammogram provides no information on the stiffness or mobility of a tumor and has a typical sensitivity of 85 percent, which decreases to 65 percent in radio-dense breasts. Meanwhile, data show that in 2005 alone more than 200,000 American women were diagnosed with breast cancer and 40,000 deaths occurred from the disease.
The PEF device consists of a hand-held probe and small electrical measurement units that can be operated by a laptop computer and eventually will be a standalone device. The PEF probe measures tissue elasticity and mobility—breast cancers are both stiffer and less mobile than surrounding tissue—and uses elasticity and mobility contrast to detect breast cancer.
The innovations of the PEF sensor include:
•Palpation-like tissue stiffness imaging both under shear and under compression with less than one-millimeter spatial resolution up to a depth of several centimeters.
•Use of the shear modulus/elastic modulus ratio to measure tumor mobility to screen for malignancy.
The key advantages of PEF are:
•The proposed PEF has better detection size sensitivity than all existing technologies –– has positively identified a 3 mm tumor missed by mammography, ultrasound, and the physician’s palpation.•It has demonstrated more than 90 percent correlation between the shear/elastic modulus ratio and tumor malignancy –– a capability all existing technologies lack.•With a single or double 1.5 cm wide PEF of depth sensitivity of 3 or 6 cm, it can probe for breast cancer for almost all body-types.•Patients are in a supine position which poses no discomfort to patients.•The PEF is gentle. It only works with less than 1 percent strain, which would cause minimal discomfort to the patient.•It is portable and can be low cost for both physicians and patients.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMolecular 'feedback loop' may explain tamoxifen resistance in patients with breast cancer
For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the…
24 September 2015
NewsBreast cancer: Care in Germany
Every year, more than 70 000 women in Germany develop an invasive breast tumor. This makes breast cancer the most common tumor disease in women. The current edition of Deutsches Ärzteblatt International (Edition 35/36)…
22 September 2015
NewsIRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone
This discovery has been patented and transferred to Inbiomotion, a spin off from the IRB Barcelona and ICREA, founded at the end of 2010. Inbiomotion, led by the venture investor Ysios Capital, has developed the…


